Literature DB >> 16889598

Impact of recipient MELD score on resource utilization.

W K Washburn1, B H Pollock, L Nichols, K V Speeg, G Halff.   

Abstract

The model for end stage liver disease (MELD) system prioritizes deceased donor organs to the sickest patients who historically require higher healthcare expenditures. Limited information exists regarding the association of recipient MELD score with resource use. Adult recipients of a primary liver allograft (n = 222) performed at a single center in the first 27 months of the MELD system were analyzed. Costs were obtained for each recipient for the 12 defined categories of resource utilization from the time of transplant until discharge. True (calculated) MELD scores were used. Inpatient transplant costs were significantly associated with recipient MELD score (r = 0.20; p = 0.002). Overall 1-year patient survival was 85.0% and was not associated with MELD score (p = 0.57, log rank test). Recipient MELD score was significantly associated with costs for pharmacy, laboratories, radiology, dialysis and physical therapy. Multivariate linear regression revealed that MELD score was most strongly associated with cost compared to other demographic and clinical factors. Recipient MELD score is correlated with transplant costs without significantly impacting survival.

Entities:  

Mesh:

Year:  2006        PMID: 16889598     DOI: 10.1111/j.1600-6143.2006.01490.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Centre volume and resource consumption in liver transplantation.

Authors:  Christopher W Macomber; Joshua J Shaw; Heena Santry; Reza F Saidi; Nicolas Jabbour; Jennifer F Tseng; Adel Bozorgzadeh; Shimul A Shah
Journal:  HPB (Oxford)       Date:  2012-06-10       Impact factor: 3.647

2.  The economic impact of addressing the organ shortage with clinically high-risk allografts.

Authors:  Krista L Lentine; Mark A Schnitzler
Journal:  Mo Med       Date:  2011 Jul-Aug

3.  Defining readmission risk factors for liver transplantation recipients.

Authors:  Neil Shankar; Paul Marotta; William Wall; Mamoun Albasheer; Roberto Hernandez-Alejandro; Natasha Chandok
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

4.  The current economic burden of cirrhosis.

Authors:  Guy W Neff; Christopher W Duncan; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

5.  Potential savings in the treatment pathway of liver transplantation: an inter-sectorial analysis of cost-rising factors.

Authors:  Lena Harries; Jill Gwiasda; Zhi Qu; Harald Schrem; Christian Krauth; Volker Eric Amelung
Journal:  Eur J Health Econ       Date:  2018-07-26

6.  The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation.

Authors:  Paolo R Salvalaggio; Nino Dzebisashvili; Kara E MacLeod; Krista L Lentine; Adrian Gheorghian; Mark A Schnitzler; Samuel Hohmann; Dorry L Segev; Sommer E Gentry; David A Axelrod
Journal:  Liver Transpl       Date:  2011-03       Impact factor: 5.799

7.  Model for end-stage liver disease (MELD) score and cost-effectiveness on living donor liver transplantation.

Authors:  Takafumi Ichida; Yutaka Narita; Romi Murakami
Journal:  J Gastroenterol       Date:  2006-10       Impact factor: 6.772

8.  Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and the Prospect of Bioengineering Autologous Liver Grafts.

Authors:  Dany Habka; David Mann; Ronald Landes; Alejandro Soto-Gutierrez
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

9.  High MELD score and extended operating time predict prolonged initial ICU stay after liver transplantation and influence the outcome.

Authors:  Panagiota Stratigopoulou; Andreas Paul; Dieter P Hoyer; Stylianos Kykalos; Fuat H Saner; Georgios C Sotiropoulos
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

10.  Symptom Burden Is Associated with Increased Emergency Department Utilization among Patients with Cirrhosis.

Authors:  Lisa X Deng; Dorothea S Kent; David L O'Riordan; Steven Z Pantilat; Jennifer C Lai; Kara E Bischoff
Journal:  J Palliat Med       Date:  2021-08-03       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.